Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

121. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

2018 Scottish Medicines Consortium

122. Core IM: Mind the Gap on COPD Classifications

How did prior understanding of COPD pathophysiology lead to COPD classifications in the past? (3:25) How is COPD diagnosed? (6:13) How has COPD been classified and why? (6:42) Subscribe to CORE IM on any podcast app! Follow us on Facebook || Twitter || Instagram . Please give any feedback at . Show Notes : Chronic Obstructive Lung Disease (COPD) , is a disease of small airway inflammation defined by at FEV1/FVC ratio less than 0.70 and symptoms of chronic bronchitis and/or emphysema. In 1998 (...) , the U.S. National Heart, Lung, and Blood Institute and the World Health Organization helped to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD) . The program’s goal was “to produce recommendations for management of COPD based on the best scientific information available.” GOLD began publishing clinical guidelines in 2001; initially they separated COPD into the clinical syndrome of “blue bloaters”, or chronic bronchitis, and “pink puffers”, or chronic emphysema, however

2018 Clinical Correlations

123. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study Full Text available with Trip Pro

Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study The associations between cardiovascular disease (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD (...) , 71.4 years; 68.9% men), retrieved from the Taiwan National Health Insurance Research Database for health care claims from 2007 to 2011.LABA or LAMA use was measured in the year preceding the event or index date, stratified by duration since initiation of LABA or LAMA treatment, new and prevalent users, concomitant COPD medications, and individual agents.Cases with inpatient or emergency care visits for coronary artery disease, heart failure, ischemic stroke, or arrhythmia were identified

2018 EvidenceUpdates

124. Endobronchial valves for patients with advanced heterogeneous emphysema

(total) Deaths from respiratory failure Deaths from COPD with cor pulmonale Expectorated valve Removal of valve Seizure (unrelated) 23 5 2 2 2 1 1 5 2 0 16 NR 2 2 0 0 0 4 2 0 22 3 0 1 0 0 0 0 0 1 20 NR 0 1 0 0 0 0 0 1 0.4 patients; 0.4 events 0.7 0.5 1.0 0.5 1.0 1.0 - - 1.0 COPD: chronic obstructive pulmonary disease; EBV: endobronchial valve. Endobronchial valves for treatment of emphysema: Update March 2017 8 Effectiveness At 3 months, improvement in mean forced expiratory volume in one second (FEV (...) -patients-emphysema/ [Accessed 14 December 2016]. 5. Choi, M., Lee, W. S. et al (2015). 'Effectiveness of bronchoscopic lung volume reduction using unilateral endobronchial valve: a systematic review and meta- analysis'. International journal of chronic obstructive pulmonary disease, 10, 703-10. 6. Jarad, N. (2016). 'Clinical review: Endobronchial valve treatment for emphysema'. Chronic respiratory disease, 13 (2), 173-88. 7. Tenda, E. D.& Yakub, A. (2016). 'Endobronchial Valve as Treatment of Emphysema

2018 COAG Health Council - Horizon Scanning Technology Briefs

125. Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations?

Format Metadata Abstract Antibiotic use reduced mortality and treatment failure in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) (strength of recommendation [SOR]: A, systematic reviews of randomized controlled trials [RCTs]). Giving antibiotics early to hospitalized patients decreased the need for later ventilation and readmission within 30 days for exacerbation of COPD (SOR: B, a retrospective cohort study). URI Citation Journal of Family Practice (...) Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? View/ Open Date 2012-09

2018 Clinical Inquiries

126. Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study Full Text available with Trip Pro

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study This multicentre, randomised, double-blind, placebo-controlled, two-period crossover study assessed the effect of umeclidinium/vilanterol (UMEC/VI) on exercise capacity in patients with chronic obstructive pulmonary disease (COPD) using the endurance shuttle walk test (ESWT). Patients were randomised 1:1 to one of two treatment sequences: 1) UMEC/VI 62.5/25 µg followed by placebo or 2) placebo followed by UMEC (...) /VI 62.5/25 µg. Each treatment was taken once daily for 12 weeks. The primary end-point was 3-h post-dose exercise endurance time (EET) at week 12. Secondary end-points included trough forced expiratory volume in 1 s (FEV1) and 3-h post-dose functional residual capacity (FRC), both at week 12. COPD Assessment Test (CAT) score at week 12 was also assessed. UMEC/VI treatment did not result in a statistically significant improvement in EET change from baseline at week 12 versus placebo (p=0.790

2018 ERJ open research Controlled trial quality: predicted high

127. Comparison of two scores of short term serious outcome in COPD patients. (Abstract)

Comparison of two scores of short term serious outcome in COPD patients. Chronic Obstructive Pulmonary Disease (COPD) related visits to the emergency department have increased substantially during the past decade. An important challenge facing emergency physicians when treating COPD patients is deciding on disposition. The aim of this study was to evaluate Integrated Pulmonary Index scoring to guide the disposition decisions of emergency physicians by comparing its compatibility with Ottawa (...) Pulmonary Index was 91.3, and the accuracy of Ottawa COPD Risk Score was 95.7.Integrated Pulmonary Index was a potential candidate for evaluating respiratory status and prediction of short-term severe events in patients with acute COPD exacerbation in emergency departments.Copyright © 2019 Elsevier Inc. All rights reserved.

2018 EvidenceUpdates

128. Roflumilast (Daxas) for maintenance treatment of severe chronic obstructive lung disease (COPD)

Roflumilast (Daxas) for maintenance treatment of severe chronic obstructive lung disease (COPD) Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung disease (COPD) | Report | National Health Care Institute You are here: Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung disease (COPD) Search within English part of National Health Care Institute Search Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung (...) disease (COPD) Zorginstituut Nederland has carried out an assessment of whether roflumilast (Daxas®) is interchangeable with a drug currently included in the Medicine Reimbursement System (GVS). Registration Roflumilast is registered as an addition to treatment with bronchodilators for the maintenance treatment of severe chronic obstructive lung disease (COPD) associated with chronic bronchitis in adults whose COPD flares up frequently. Roflumilast is available as 500 microgram film-coated tablets

2018 National Health Care Institute (Zorginstituut Nederland)

129. General medicine: Tiotropium could provide benefits in the early stage of COPD, but further studies are needed

established if we must use long-acting bronchodilators in all patients with COPD. This is a critical issue because many patients suffering from COPD do not complain about the classic disturbing symptoms of COPD such as cough, sputum and dyspnoea, despite the present of a mild and even moderate airflow obstruction as measured by spirometry. 2 , 3 Methods A multicentre randomised trial 4 of over 800 Chinese COPD patients with mild to moderate [Global Initiative for Chronic Obstructive Lung Disease (GOLD (...) of COPD, but further studies are needed Mario Cazzola , Paola Rogliani Statistics from Altmetric.com Commentary on : Zhou Y, Zhong NS, Li X, et al . Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med . 2017;377:923–935. Context Although bronchodilators are the first-line maintenance treatment for chronic obstructive pulmonary disease (COPD), we still ignore what their real role is in treating obstructed asymptomatic patients. 1 For this reason it is still not well

2018 Evidence-Based Medicine

130. Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD)

. Indications: Chronic obstructive pulmonary disease (COPD) Manufacturer Requested Reimbursement Criteria 1 : For the long-term, once daily, maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, where the following clinical criteria are met: - Moderate to severe COPD as defined by spirometry; and - At risk of exacerbations despite a long-acting bronchodilator (LAMA or LABA); or - Symptomatic or at risk of exacerbations despite a LAMA/LABA (...) Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD) fluticasone furoate/umeclidinium/vilanterol | CADTH.ca Find the information you need fluticasone furoate/umeclidinium/vilanterol fluticasone furoate/umeclidinium/vilanterol Last Updated: September 19, 2018 Result type: Reports Project Number: SR0562-000 Product Line: Generic Name: fluticasone furoate umeclidinium vilanterol Brand Name: Trelegy Ellipta Manufacturer: GlaxoSmithKline Inc

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

131. Short-Term Effects of Normocapnic Hyperpnea and Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. (Abstract)

Short-Term Effects of Normocapnic Hyperpnea and Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. The aim of the study was to evaluate the short-term physiologic effects of respiratory muscle training with normocapnic hyperpnea added to standard exercise training on respiratory muscle endurance/strength and exercise tolerance in patients with chronic obstructive pulmonary disease.The study used a randomized controlled trial. Patients referred (...) training alone, improves respiratory muscle endurance and strength but not exercise tolerance in patients with chronic obstructive pulmonary disease.

2018 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

132. Randomised controlled trial: Non-invasive positive pressure ventilation should be considered in patients with COPD and persistent hypercapnia at least 2 weeks after resolution of acute respiratory failure

noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017;317:2177–86. Implications for practice and research Non-invasive positive pressure ventilation (NPPV) should be considered in patients with chronic obstructive pulmonary disease (COPD) with persistent hypercapnia 2–4 weeks after resolution of acute respiratory failure. Timely follow-up after hospitalisation for acute respiratory (...) failure is important. Further trials are needed to confirm the findings and to clarify which patients benefit most, the role of concurrent obstructive sleep apnoeas and optimal ventilator settings of NPPV in stable hypercapnic COPD. Context NPPV improves outcomes and should be standard care in patients with acute hypercapnic respiratory failure, indicated by respiratory acidosis, in COPD. 1 Chronic hypercapnia is … Request Permissions If you wish to reuse any or all of this article please use the link

2018 Evidence-Based Nursing

133. Overview of COPD

Overview of COPD Overview of COPD - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of COPD Last reviewed: February 2019 Last updated: June 2018 Introduction Chronic obstructive pulmonary disease (COPD) is a disorder that is usually progressive, characterised by airflow limitation that is not fully reversible. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350 (...) . 2010;363:1128-1138. http://www.nejm.org/doi/full/10.1056/NEJMoa0909883 http://www.ncbi.nlm.nih.gov/pubmed/20843247?tool=bestpractice.com and may themselves accelerate the progression of COPD. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852. http://www.ncbi.nlm.nih.gov/pubmed/12324669?tool=bestpractice.com In addition to the usual therapies used for COPD, antibiotics have

2018 BMJ Best Practice

134. Acute exacerbation of chronic obstructive pulmonary disease

) and/or diarrhoea, including Clostridium difficile -associated diarrhoea (associated with the use of antibiotics). Definition Chronic obstructive pulmonary disease (COPD) is "a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases." Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis (...) , management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication] http://goldcopd.org/gold-reports/ An exacerbation of COPD may be defined as "an acute worsening of respiratory symptoms that results in additional therapy." Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication] http://goldcopd.org/gold-reports/ History and exam

2018 BMJ Best Practice

135. COPD

COPD COPD - Symptoms, diagnosis and treatment | BMJ Best Practice   Search  COPD Last reviewed: February 2019 Last updated: November 2018 Summary Progressive disease state characterised by airflow limitation that is not fully reversible. Suspected in patients with a history of smoking, occupational and environmental risk factors, or a personal or family history of chronic lung disease. Presents with progressive shortness of breath, wheeze, cough, and sputum production, including haemoptysis (...) characterised by airflow limitation that is not fully reversible. It encompasses both emphysema and chronic bronchitis. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. It is primarily caused by cigarette smoking. Although COPD affects the lungs, it also has significant systemic consequences. Exacerbations and comorbidities are important contributors to the overall condition and prognosis in individual patients

2018 BMJ Best Practice

136. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Full Text available with Trip Pro

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged (...) 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory volume in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 versus 1.13 exacerbations·patient

2018 EvidenceUpdates Controlled trial quality: predicted high

137. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD Full Text available with Trip Pro

with moderate to very severe airflow limitation and a broad range of COPD symptoms.These post hoc analyses of pooled data investigated whether baseline symptom burden, assessed using the COPD Assessment Test (CAT) score, impacted GFF MDI-associated improvements in lung function, health status, rescue medication use, and exacerbation risk.In 3,699 patients, improvement in FEV1 at week 24 between the GFF MDI and monocomponent MDIs and a placebo MDI was similar in magnitude regardless of baseline CAT score (...) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients

2018 EvidenceUpdates

138. A simple algorithm for the identification of clinical COPD phenotypes Full Text available with Trip Pro

A simple algorithm for the identification of clinical COPD phenotypes This study aimed to identify simple rules for allocating chronic obstructive pulmonary disease (COPD) patients to clinical phenotypes identified by cluster analyses.Data from 2409 COPD patients of French/Belgian COPD cohorts were analysed using cluster analysis resulting in the identification of subgroups, for which clinical relevance was determined by comparing 3-year all-cause mortality. Classification and regression trees (...) (CARTs) were used to develop an algorithm for allocating patients to these subgroups. This algorithm was tested in 3651 patients from the COPD Cohorts Collaborative International Assessment (3CIA) initiative.Cluster analysis identified five subgroups of COPD patients with different clinical characteristics (especially regarding severity of respiratory disease and the presence of cardiovascular comorbidities and diabetes). The CART-based algorithm indicated that the variables relevant for patient

2018 EvidenceUpdates

139. Endobronchial valve insertion to reduce lung volume in emphysema

, a radiologist, a thoracic surgeon and a respiratory nurse. 1.3 Patients selected for treatment should have had pulmonary rehabilitation. 1.4 The procedure should only be done to occlude volumes of the lung where there is no collateral ventilation, by clinicians with specific training in doing the procedure. 2 2 Indications and current treatments Indications and current treatments 2.1 Emphysema is a chronic lung disease in which the walls of the air sacs (alveoli) in the lungs weaken and disintegrate (...) of 3 RCTs (n=482) in the SR. Serious adverse events were reported on 22 occasions in patients treated by umbrella EBV and in 6 patients having SMC in 1 RCT (n=277) included in the SR. The rate of adverse events was statistically significantly higher in patients treated by umbrella EBV than in those having SMC (OR 3.41, 95% CI 1.48 to 7.84) in a meta-analysis of 2 RCTs (n=350) in the SR. 5.3 Chronic obstructive pulmonary disease (COPD) exacerbation episodes were not statistically significantly more

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

140. Managing stable chronic obstructive pulmonary disease — focusing on inhalers

Managing stable chronic obstructive pulmonary disease — focusing on inhalers '); } else { document.write(' '); } ACE | Managing stable chronic obstructive pulmonary disease — focusing on inhalers Search > > Managing stable chronic obstructive pulmonary disease — focusing on inhalers - Managing stable chronic obstructive pulmonary disease — focusing on inhalers Published on 25 September 2018 This Appropriate Care Guide (ACG) outlines the overall recommendations to managing stable COPD

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)